Studies have shown that PEI occurs in more than 85% of patients with cystic fibrosis.1 Malnutrition and growth retardation are important prognostic factors in children with cystic fibrosis and both may adversely affect the course of the disease with declining lung function and poor outcomes.2 Population-based studies in both adults and children with cystic fibrosis have shown a clear association between normal growth status and both pulmonary function and survival.3
Adult cystic fibrosis and PEI
Following a parallel design of 2 randomised placebo-controlled studies with an open-label run-in-phase whereby all patients were stabilised on Creon®, patients who were then randomised to Creon® experienced positive improvement in the mean coefficient of fat absorption (CFA), unlike those randomised to placebo, whose mean CFA decreased significantly (p<0.001).4
Dose of pancreatin: 4537.8 mean lipase units/kg/day.
Adapted from Stern RC et al. Am J Gastroenterol 2000.
Infant and child cystic fibrosis and PEI
In infants with cystic fibrosis aged 1 to 24 months, Creon® produced a rapid improvement in mean coefficient of fat absorption (CFA).2
CFA:Coefficient of fat absorption
Adapted from Colombo C et al. Pancreas 2009.
Furthermore, treatment with Creon® Micro was found to:2
- increase length and weight over 8 weeks
- decrease the proportion of patients with steatorrhoea from 100% to 58% at 2 weeks
- increase the number of patients with normal stool characteristics at 2 weeks
- reduce mean faecal energy loss at 2 weeks
- Littlewood JM et al. Pediatric Pulmonology 2006; 41: 35-49.
- Colombo C et al. Pancreas 2009; 38: 693-9.
- Stallings VA et al. J Am Diet Assoc. 2008; 108: 832-9.
- Stern RC et al. Am J Gastro 2000; 95(8): 1932–1938.